M
Malte Buchholz
Researcher at University of Marburg
Publications - 112
Citations - 5377
Malte Buchholz is an academic researcher from University of Marburg. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 34, co-authored 102 publications receiving 4718 citations. Previous affiliations of Malte Buchholz include University of Ulm & University of Göttingen.
Papers
More filters
Journal ArticleDOI
Stromal biology and therapy in pancreatic cancer
Albrecht Neesse,Patrick Michl,Kristopher K. Frese,Christine Feig,Natalie Cook,Mike A Jacobetz,Martijn P. Lolkema,Malte Buchholz,Kenneth P. Olive,Thomas M. Gress,David A. Tuveson +10 more
TL;DR: Stromal cells contained within the PDA tumour microenvironment represent an additional constituent to neoplastic cells that should be critically evaluated for optimal therapeutic development in preclinical models and early clinical trials.
Journal ArticleDOI
StellaTUM: current consensus and discussion on pancreatic stellate cell research
Mert Erkan,Guido Adler,Minoti V. Apte,Max G. Bachem,Malte Buchholz,Sönke Detlefsen,Irene Esposito,Helmut Friess,Thomas M. Gress,Hans Joerg Habisch,Rosa F. Hwang,Robert Jaster,Jörg Kleeff,Günter Klöppel,Claus Kordes,Craig D. Logsdon,Atsushi Masamune,Christoph W. Michalski,Junseo Oh,Phoebe A. Phillips,Massimo Pinzani,Carolin Reiser-Erkan,Hidekazu Tsukamoto,Jeremy S. Wilson +23 more
TL;DR: Members of the Pancreatic Star Alliance discuss and consolidate current knowledge to outline and delineate areas of consensus or otherwise (eg, with regard to methodological approaches) and, more importantly, to identify essential directions for future research.
Journal ArticleDOI
Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.
Patrick Michl,Malte Buchholz,Monika Rolke,S Kunsch,Matthias Löhr,Bruce A. McClane,Shoichiro Tsukita,Gerhard Leder,Guido Adler,Thomas M. Gress +9 more
TL;DR: The findings suggest that targeting claudin-4-expressing tumors with CPE represents a promising new treatment modality for pancreatic cancer and other solid tumors.
Journal Article
Claudin-4 Expression Decreases Invasiveness and Metastatic Potential of Pancreatic Cancer
Patrick Michl,Claudia Barth,Malte Buchholz,Markus M. Lerch,Monika Rolke,Karlheinz Holzmann,Andre Menke,Heiko Fensterer,Klaudia Giehl,Matthias Löhr,Gerhard Leder,Takeshi Iwamura,Guido Adler,Thomas M. Gress +13 more
TL;DR: Claudin-4 is identified as a potent inhibitor of the invasiveness and metastatic phenotype of pancreatic cancer cells, and as a target of the transforming growth factor beta and Ras/Raf/extracellular signal-regulated kinase pathways.
Journal ArticleDOI
Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway.
Malte Buchholz,Malte Buchholz,Alexandra Schatz,Martin Wagner,Patrick Michl,T. Linhart,Guido Adler,Thomas M. Gress,Thomas M. Gress,Volker Ellenrieder,Volker Ellenrieder +10 more
TL;DR: It is demonstrated that ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway is an important mechanism of oncogenic c‐myc activation in pancreatic cancer.